Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
Katelyn M AtkinsMing-Hui ChenJing WuAndrew A RenshawMarian LoffredoPhilip W KantoffEric J SmallAnthony V D'AmicoPublished in: Cancer (2017)
Low, but not necessarily castrate, testosterone levels at the time of PSA failure confer a very poor prognosis. These observations provide evidence to support testosterone testing at the time of PSA failure. Given prolonged survival when abiraterone or docetaxel is added to ADT in men with castrate-sensitive metastatic PC and possibly localized high-risk PC provides a rationale supporting their use with ADT in men with low testosterone in the setting of a phase 2 trial. Cancer 2018;124:1383-90. © 2017 American Cancer Society.
Keyphrases
- prostate cancer
- poor prognosis
- replacement therapy
- clinical trial
- papillary thyroid
- radical prostatectomy
- long non coding rna
- middle aged
- squamous cell
- squamous cell carcinoma
- small cell lung cancer
- lymph node metastasis
- radiation therapy
- randomized controlled trial
- smoking cessation
- locally advanced
- open label
- study protocol
- phase ii
- rectal cancer
- free survival
- phase iii